| Outcome Measures: |
Primary: Microcirculation, Assessment of microcirculatory changes using laser doppler, Baseline and 24 weeks | Secondary: Interleukins, Serum interleukins (IL) will be determined by enzyme-linked immunosorbent assay (Bio-Rad 680 Microplate Reader, USA) using the appropriate sets of reagents for enzyme immunoassay to determine the concentration of IL-1β (reference values 0-5.0 pg/ml), IL-6 (reference values 0-7.0 pg/ml), IL-10 (reference values 0-9.1 pg/ml), (Vector-Best, Novosibirsk, Russia) compared from baseline, Baseline and 24 weeks|Tumor necrosis factor-α (TNFα), Tumor necrosis factor-α (TNFα) will be determined by enzyme-linked immunosorbent assay (Bio-Rad 680 Microplate Reader, USA) using the appropriate sets of reagents for enzyme immunoassay to determine the concentration of TNFα (reference values 0-8.21 pg/ml) (Vector-Best, Novosibirsk, Russia), Baseline and 24 weeks|Neuropathy disability score, Using standard scoring systems and questionnaires. Scoring is: Neuropathy disability score (0-10),, Baseline and 24 weeks|Pain score, Patients will be asked to score pain on a visual analog scale 0-10 with 10 being the worst pain ever, Baseline and 24 weeks|Neuropathic symptom score, This will be scored using standard questionnaire 0-9, Baseline and 24 weeks
|
